The Buzz Surrounding: Mydecine Innovations Group Inc. (OTC: NLBIF) (CSE: MYCO) | Financial Buzz

The Buzz Surrounding: Mydecine Innovations Group Inc. (OTC: MYCOF) (CSE: MYCO)

About Mydecine Innovations Group Inc.

Mydecine Innovations Group Inc. is a parent company which operates innovative product divisions in the Naturally Sourced Therapies (NST) space. Mydecine Innovations Group Inc. operates a number of hemp-derived CBD and psilocybin brands that design, manufacture and distribute cutting edge products. Mydecine Innovations Group Inc. further enhances their portfolio with cultivation properties, land assets and retail space.

Our Buzz on the Street Show Featuring Mydecine Innovations Group Inc.

Investor Recap

Agreement with Applied Pharmaceutical Innovation

Mydecine Innovations Group Inc. announced the establishment of a research division agreement with Applied Pharmaceutical Innovation (“API”), a translational commercial drug development institute hosted in the University of Alberta’s 
Faculty of Pharmacy and Pharmaceutical Sciences.

 

The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities. The Faculty of Pharmacy and Pharmaceutical Sciences is consistently ranked in the top 15 globally for the citations of research by international QS rankings in pharmacy and pharmacology and includes a wide range of experts from discovery, pharmaceutical analysis, drug action, disposition, formulation and clinical development.[1] Mydecine is also able to access broader expertise through the agreement such as API’s collaborating institute the Alberta Machine Intelligence Institute (Amii) – ranked among the top 5 institutes in the world for AI/ML[2] – as well as experts in mycology, pharmacometrics, neuropharmacology and much more at universities throughout the API network.

 

Mindleap Health we are focused on positively impacting society through a disruptive platform for psychedelic aftercare and by developing new forms of medicine.

Technology

Mindleap is a digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind. Online mental healthcare brings convenience, improves access to treatments and can lead to more personal breakthroughs. Mindleap’s proprietary platform is designed by clinical psychologists and neuroscientists to provide professional support and personalized treatment for every person.

The Mindleap platform will provide support for people that are looking to achieve personal transformations and overcome mental health challenges. Mindleap is the only digital health platform that combines telehealth with mood, emotion and habit tracking. 

 

Mydecine Farms aims to be a pioneer in the cultivation and genetic IP development of mushrooms and Fungi. The Company is comprised of scientific and horticulture experts that have years of experience in the isolation of compounds, genetic composition development, large scale horticulture and IP and patent formulation. 

Mydecine Wellness is a revolutionary product developer and manufacturer of a variety of proprietary formulated nutraceutical and supplemental products based on the use of various strains of mushrooms and fungi. The Company will leverage its science, research, product development and marketing expertise to utilize the vast benefits of various compounds found within certain strains of mushroom and fungi found throughout the world.

Mydecine Labs will be a trailblazer in the research, development and discovery of groundbreaking IP derived from psychedelic compounds, namely psilocybin, found in various strains of mushroom and fungi. The Company intends to have a two prong approach both public and private, leveraging its extensive science team as well as partnerships with pertinent departments of major universities.

Know Your Mushrooms

 CORDYCEPS(Cordyceps militaris)

Traditionally used for energy, lung capacity, ATP production, athletic performance, sexual performance, kidneys,  QI, anti-parasitic anti-aging, etc.*

 REISHI (Ganoderma Lucidum)

Traditionally used for immune system health, inflammation, and allergies, cardiovascular system, sleep, relaxation, neuro-protection, anti-aging, lungs, liver, kidneys, etc.*

 CHAGO (Inonotus obliquus)

Traditionally used for Immune System support, Anti-oxidants, UV protection, Digestion, anti-viral, inflammation, detox, etc.*

 LIONS MANE (Hericium erinaceus)

Traditionally used for brain/cognitive function, Memory, preventing Alzheimer and dementia, Nervous system, nerve damage, digestion etc.*

• TURKEY TAIL (Trametes versicolor)

Traditionally used for immune function, cancer, chemotherapy and radiotherapy, HIV, herpes, chronic fatigue, liver health etc.*

 MAITAKE (Grifola frondosa)

Traditionally used for blood pressure, blood sugar level, nervous system, hypertension, cholesterol, stomach, spleen, immune system, side effects of chemo/radiotherapy etc.*

 SHIITAKE (lentinufa erodes)

Traditionally used for anti-viral, cholesterol, liver function, HIV, anti-microbial, anti-candida, chemotherapy, immune system, etc*

 MESHIMA (Phellinus linteus)

Traditionally used for Women’s health, healthy breast cells, immune function, DNA protection, anti-viral, a tibacterial, anti-oxidant, anti-tumor, etc.*

 TREMELLA (Tremella fuciformis)

Traditionally used for skin health, complexion, bones, memory, weight management, lungs, dry cough, stomach, kidney, liver, anti-tumor, Qi tonic, Immune System.*

 PORIA COCOS (Wolfiporia extensa)

Traditionally used for inflammation, diuretic, rest, relaxation and sleep, depression, memory, spleen, stomach, fluid retention, nervous system, anti- tumor, anti-bacterial.*

 PSILOCYBIN

Biological genera containing psilocybin mushrooms include CopelandiaGymnopilusInocybePanaeolus, Pholiotina
Pluteus, and Psilocybe. Psilocybin mushrooms may have been used in ancient religious rites and ceremonies. They may be depicted in Stone Age Rock Art Africa and Europe, but are most famously represented in the Pre-Columbian sculptures and glyphs seen throughout Central and South America*

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Recent Developments

In the Media

Innovative, Psychedelic Treatments In Development For Veterans

Can psychedelic medicine be a groundbreaking treatment for veterans and frontline workers?

Press Releases

July 21, 2020 - Mindleap Health Signs Agreement with Brightmind to Launch Comprehensive Meditation Program

Mydecine Innovations Group Inc. (CSE: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health Inc. ( “Mindleap” ) has signed an agreement dated July 21, 2020  with Brightmind (“Brightmind”) to launch a comprehensive meditation program on Mindleap’s advanced digital health platform. Under the terms of the agreement Brightmind will provide specialised meditation content to Mindleap and Mindleap will make that content available for purchase on the platform.

Brightmind is a leading meditation app that provides customized and practical instruction by world-class meditation experts. Brightmind offers a robust curriculum that is based on an approach to teaching developed over the past 40 years by the esteemed meditation educator Shinzen Young.

Brightmind is the first and only app that makes Shinzen’s powerful system easily available. The Brightmind app has been downloaded over 100,000 times and has been featured by Apple in their coveted “New Apps We Love” section, as well as Forbes and Huffington Post. Shinzen’s system is so clear and well organized that neuroscience researchers at Harvard and other top universities use his system to design their experiments and have brought Shinzen on as a research consultant.

Mindleap Founder and CEO Nikolai Vassev commented: “Our vision is for a world where people can make lasting life changes by having advanced tools and access to expert mental health professionals right from the palm of their hand. Mindfulness can have numerous benefits, everything from decreased stress and sadness to increased levels of happiness and focus. Brightmind’s programs have provided radical transformations for thousands of people and the partnership with Mindleap should lead to more value for our customers and platform.”

Over the past 20 years, meditation and mindfulness-based programs have become increasingly popular. Doctors and mental health professionals are embracing meditation because scientific studies are beginning to show that it works, particularly for stress-related conditions.

The market for meditation apps has exploded into the mainstream and shows little sign of slowing down. In 2019 alone, the meditation market reached $1.2 Billion (USD). Employers are embracing mindfulness training and leading apps like Headspace and Calm are reaching over 50 million downloads while commanding billion dollar valuations. The major players offer relatively simple and shallow meditation instruction, which their users quickly exhaust while Brightmind’s comprehensive and proven programs offer a much more robust value to end users.

Meditation, when practiced and contextualized well, is one of the most effective methods for improving mental health.

Brightmind Founder and CEO Toby Sola commented: “Meditation is a way to upgrade our mental software to meet the demands of our rapidly changing world. We have been hard at work to deliver exceptional programs and are thrilled to collaborate with Mindleap so we can deliver our programs to even more people.”

The Brightmind Meditation program will be a part of five other digital health programs that will be offered on Mindleap later this fall. The scalability, consistency, and reduced costs to end users create more comprehensive and versatile offering for the Mindleap platform.

 For Full Press Release – https://www.prnewswire.com/news-releases/mindleap-health-signs-agreement-with-brightmind-to-launch-comprehensive-meditation-program-301096722.html

July 16, 2020 - Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute

 

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. (“NeuroPharm”), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in veterans and frontline workers, has entered into a collaborative relationship with Leiden University Medical Center of The Netherlands (“LUMC”) for the initiation of clinical trials. The project, “NeuroPharm Veteran PTSD Research Project (NVPRP),” is preparing an IRB-ready protocol to be used for a LUMC based clinical trial for the specific treatment of PTSD in veterans. ARQ National Psychotrauma Centre will also play a significant role in the execution of this trial.

LUMC is the hospital affiliated with Leiden University located in Leiden, Netherlands. Leiden University, founded in 1575, is one of Europe’s leading international research universities.  NeuroPharm selected LUMC due to its established position as a world-recognized leader in the research and study of psilocybin (a psychedelic chemical naturally found in certain varietals of mushrooms). In previous work, Leiden University researchers have found that micro doses of psilocybin can stimulate brain function without harming reasoning abilities. The NVPRP will couple NeuroPharm’s scientific, academic, and clinical trial expertise with LUMC’s leading edge psilocybin research and development.

Leading the Leiden work on NeuroPharm’s behalf is Professor H.G.J.M. (Eric) Vermetten MD, Ph.D. Colonel, an internationally recognized leader in the treatment of PTSD and other mental disorders. Dr. Vermetten, an active Colonel of the Dutch military, serves as professor Medical-Biological and Psychiatric Aspects of Psychotrauma, LUMC/University of Leiden. Dr. Vermetten is psychiatrist at the MGGZ in Utrecht (Military Mental Health care) and has served as a researcher in conjunction with Stanford University, Yale University and Emory University.

The protocols being developed with Dr. Vermetten are to be employed for veteran-based clinical trials for the treatment of PTSD with psilocybin assisted psychotherapy. The inceptive LUMC trial will serve as the basis for a series of follow-on trials conducted in Canada and the United States.

“Despite several evidence-based treatment options for Veterans suffering with PTSD, we know that many still do not respond. It is important to continue the search for safe and effective treatments to help those that are suffering after sacrificing so much for nations,” Dr Vermetten stated.

“Psilocybin assisted psychotherapy has the potential to be a game changer in the treatment of PTSD in Veterans and it seems natural that a Dutch/Canadian collaboration will lead the way,” Dr. Rekesh Jetly added, COO of NeuroPharm.

The Company’s prospective acquisition of 100% of the issued and outstanding shares of NeuroPharm (the “Acquisition”) is subject to a number of conditions, including, but not limited to, completion of satisfactory due diligence and regulatory approval. There can be no assurance that the Acquisition will be completed as proposed, or at all.

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-inc-announces-neuropharm-inc-commences-ptsd-clinical-trial-initiative-with-leading-european-research-institute-301094537.html

July 14, 2020 - Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc.

 

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce that, further to its press release on June 10, 2020, it has entered into a definitive share exchange agreement (the “Share Exchange Agreement”) for the acquisition (the ” Acquisition “) of 100% of NeuroPharm Inc. (“NeuroPharm”), a Canadian-based developer of natural psychedelic-based treatments for mental health disorders in the Canadian and United States veteran communities.

NeuroPharm, in collaboration with its strategic partners, is deploying evidence-based medicine in the establishment of psychedelic-based therapies addressing the unmet needs of high-risk constituents. NeuroPharm is focused on developing unique and proprietary technologies to treat various mental health conditions frequently experienced by veterans and frontline workers such as PTSD, depression, addiction, anxiety, and panic disorders as well as migraine and cluster headaches.

NeuroPharm’s management team is composed of critically acclaimed scientists and military personnel boasting extensive drug development experience and deep, embedded relationships within the Canadian and U.S. militaries. It has established valuable partnerships with leading research organizations in both North America and the EU, and is poised to initiate a series of unique clinical trials this summer.  In conjunction with a preeminent university in the EU, NeuroPharm will be initiating veteran-based clinical trials for the treatment of PTSD with microdosed MDMA/psilocybin formulations.  This inceptive trial will serve as the basis for follow-on trials conducted in Canada and the United States. NeuroPharm’s veteran focus allows for fast-track “adaptive pathways” which should significantly reduce time to market. 

NeuroPharm boasts extensive established relationships with global military organizations and a distinguished team of inter-disciplinary experts. Its commitment to excellence and stewardship uniquely positions NeuroPharm to oversee all areas of the product life cycle, including medical mushroom cultivation, drug delivery system development, clinical trial execution, all the way through to product commercialization.

“According to recent published data, as many as 20 veterans on average commit suicide per day in the U.S. alone, and, to me, this is a heart-breaking staggering statistic that unfortunately is overlooked by so many. We owe everything to our veterans, EMS and frontline personnel, yet the best solutions for their long-term mental health are currently non-existent. Aligning ourselves with the amazing team at NeuroPharm affords us the ability to make a positive change. Myself and the rest of the Mydecine team are truly honoured to be a part of this effort to finally make a difference and we are incredibly excited about what we will all accomplish together,” stated Josh Bartch, CEO of Mydecine.

Colonel (Ret’d) Pucci, CEO of NeuroPharm further commented:

“Our mission is to develop and bring to market treatments addressing the mental health conditions frequently experienced by veterans, including PTSD, depression and anxiety.  We understand the unique circumstances of the veteran community and are devoted to treating these substantial unmet needs.  Our collaborative partnership with Mydecine will accelerate our ability to address the enormous challenge of restoring the overall wellness in the veteran, EMS and frontline personnel communities. We are most pleased to be part of the Mydecine family of companies.”

Mydecine and NeuroPharm will unite to focus on an integrated health and wellness research strategy and the development of products underpinned by therapies to assist veterans with mental health issues. The Acquisition will help establish Mydecine as one of the world’s leading authorities in psychedelic-based therapies and research, and maintain the Company’s status as a true market leader…

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-inc-signs-definitive-agreement-for-acquisition-of-neuropharm-inc-301092903.html

July 7, 2020 - Mydecine Innovations Group Adds World Renowned, 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to Its Scientific Advisory Board

 

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.

Dr. Reddy is one of the world’s most pre-eminent authorities in applied microbiology as it relates to dairy foods, probiotics, and pollution mitigation. He holds over 150 U.S. and international patents, of which more than 100 are used daily in international commerce. He has also published over 70 scientific articles and has written several best selling books, including ‘A to Z of Success: 26 Keys to Winning’.

Also known as the “Cheese King’  due to his wildly successful cheese and dairy-based biotechnology company, Dr. Reddy currently serves as the Chairman and President of USA-based American Dairy and Food Consulting Laboratories, and International Media and Cultures.

Nominated for the 2012 Nobel Peace Prize by the Chair of the United States Association of the state of Colorado, Dr. Reddy has received accolades and over 100 national and international awards and honors from all over the world.

Some of his more notable awards include: Richard M. Hoyt Memorial award from the American Dairy Science Association, Outstanding Young Alumnus Recognition award from the Iowa State University, Sigma-Xi Research award, Outstanding Scientist award from IAFC, Washington, D.C., 2003, 2004 and 2005, Outstanding Businessman of the Year award, and the prestigious U.S. President Ronald Reagan Gold Medal award in Washington, D.C.

As Scientific Advisor, Dr. Reddy will be responsible for overseeing the Company’s 7,500 sq. ft mycology lab in Denver, Colorado and will assist in the development of proprietary therapies using bacteria and rare fungal strains.

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-adds-world-renowned-7-time-nobel-peace-prize-nominee-dr-ms-reddy-to-its-scientific-advisory-board-301088834.html

June 30, 2020 - Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board

 

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.

Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last 30 years. He holds numerous patents and has been published extensively in the field of medicinal chemistry and drug research. Dr. Hoyer has unparalleled expertise in computational chemistry enabled probe molecule design, drug design and optimization, synthetic planning and execution, evaluation of chemical novelty and intellectual property assessment and strategies.

As part of his role with the company, Dr. Hoyer will directly work with Mydecine CSO Rob Roscow in developing research strategies, computational assessment of drug properties, formulation and pharmacokinetic studies as well as synthetic chemistry of drug substances.

“Dr. Hoyer’s decades of experience in drug discovery, genetics, pharmacology and intellectual property are going to be instrumental to our long term success,” expressed Rob Roscow.

Most recently, Dr. Hoyer served as the Director of Chemistry for the Yale Center for Molecular Discovery, where he led a team of scientists collaborating with Yale investigators to translate academic research into novel therapies for diseases across multiple therapeutic areas.

During his time at Pfizer, Dr. Hoyer held a joint appointment to both medicinal and computational groups developing a unique perspective and approach to lead finding and optimization. His deep knowledge of ADME and in-silico filtering provided Pfizer with novel properties screens and improved the quality of their screening collections. While at Novartis, Dr. Hoyer worked on compounding physical properties and ADME and created a novel approach to solubility determinations, later dubbed “kinetic” solubility.

Dr. Hoyer TSX obtained his Ph.D. with A. I. Meyers at Colorado State University developing new synthetic methodology followed by post-doctoral studies in Chemical Biology with Peter G. Schultz at the University of California, Berkeley.

“Dr. Hoyer will provide Mydecine strategic support with the entire process of drug discovery from target conception, through drug design and selection of clinical candidates. He will be instrumental to our R&D efforts at our Innovation center in Denver as well as the University of Alberta,” added Mydecine CEO Josh Bartch.

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-adds-former-pfizer-novartis-yale-drug-discovery-expert-to-scientific-advisory-board-301085584.html

June 23, 2020 - Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

 

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) (“Mydecine” or the “Company”), is pleased to announce the addition of two key strategic advisors to the company’s Scientific Advisory Committee.

The new members of the science team will provide scientific expertise and corporate strategy support as Mydecine begins its R&D program at its Innovation Center in Denver, Colorado. The advisory committee will review/monitor/access specific protocols and serve as an advocate for the organization providing technical expertise and collaborating with team members to help shape the direction of the various research programs.

Vince Polito is a Research Fellow at Macquarie University and former Associate Investigator at the Australian Research Council Centre of Excellence in Cognition and its Disorders. Mr. Polito’s research aims to understand how self-monitoring changes, self-representation, sense of agency, belief formation and altered states of consciousness. Vince’s research has been profiled in The Guardian, BBC, Buzzfeed, Nine News, Vice and many others.

Last year Mr. Polito conducted one of the largest to date Microdosing of psychedelics studies. In this research his team investigated the short- and long-term effects of microdosing on wellbeing, cognition and agency. The study conducted was a systematic, observational investigation of individuals who microdose (regular ingestion of very small quantities of psychedelic substances). The study tracked the experiences of microdosing participants, who provided daily ratings of psychological functioning over a six-week period and completed a battery of psychometric measures tapping mood, attention, wellbeing, mystical experiences, personality, creativity, and sense of agency, at baseline and at completion of the study. Analysis of pre and post study measures revealed reductions in reported levels of depression and stress; lower levels of distractibility; increased absorption; and increased neuroticism.

Anton Gomez-Escolar is a Psychopharmacology expert based in Madrid, Spain. Mr. Gomez-Escolar has a technical understanding of neurobiology, psychopharmacology, psychedelics, nootropics, drug safety and clinical trial development. Mr. Gomez-Escolar has a Masters in Psychopharmacology from Spain’s largest university Complutense University of Madrid, including a Master Thesis on the topic of “Psychedelics in psychotherapy for the treatment of depression and addiction”, a Masters in International Relations by Griffith University from Australia, and many other diplomas including a certificate of Design and Interpretation of Clinical Trials from John Hopkins School of Public Health, a certificate in Drug Discovery, Development & Commercialization from UCSD and a certificate in Drug Use, Policy and Health from the University of Geneva.

Mr. Gomez-Escolar is the co-founder the Psychedelic Society of Madrid, attended and presented in many international conferences on the topic and has worked for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the official European Union drugs information agency as well as Laboratorios Equisalud, a leading laboratory in holistic phytotherapy and nutritional supplements.

Rob Roscow, CSO and Director commented: “Our Scientific Advisory Board provides Mydecine independent, expert, multi-disciplinary, and strategic advice on scientific programs, emerging health science issues and trends in the psychedelic medicine sector. We are actively expanding our operations and we are thrilled to add these two talented individuals to our growing team.”

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-bolsters-scientific-advisory-board-adding-a-leading-neuroscientist-and-a-psychopharmacology-specialist-301081602.html

June 17, 2020 - Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform

Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) (“Mydecine” or the “Company”) is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. (“Mindleap”) for the acquisition of a 100% interest in MindLeap’s Digital Telehealth Platform focused on the emerging psychedelics industry.

Pursuant to the share exchange agreement, Mydecine will acquire 100% of the issued and outstanding shares of Mindleap in exchange for: (i) 6,363,636 common shares in the capital of the Company, and (ii) the binding commitment to advance CAD $500,000 in working capital to Mindleap upon closing of the transaction and an additional CAD $500,000 on or before September 1, 2020. Certain principals of Mindleap will be subject to resale restrictions on the sale of the Mydecine shares for the periods ending 4, 12, 18, and 24 months from closing. Closing of the acquisition is subject to the receipt by Mindleap of the signatures of all of its shareholders on the share exchange agreement.

Mental health has been a big issue and is a major focus for the Mydecine Group of companies. Currently the World Health Organization estimates that there are more than 450 million people suffer from mental health disorders worldwide placing mental disorders among the leading causes of ill-health and disability worldwide. The US has the highest prevalence of mental health disorders in the world with 27 percent of adults, yet only 41 percent of the people who had a mental disorder in the past year received professional health care or other mental health services due to convenience and cost associated.

Mydecine Director and CEO, Josh Bartch, stated: “This acquisition brings Mydecine an elite team drawn from tech, mental health, and science, paired with innovative technology with a strong USP and large addressable market. The scalability of the platform means high potential return on investment especially given Mindleap’s 1st mover advantage in the rapidly emerging psychedelic medicine sector.”

Mindleap is focused on making a considerable difference in people’s lives by improving access to mental health services and providing more personalized and effective treatments utilizing the latest technology. The Mindleap Platform upon launch will provide:  

  • Convenient and more affordable access to mental health services
  • Psychedelic aftercare, addiction, and holistic wellness services
  • On Demand access to mental health programs
  • Automated appointment booking and international payments
  • Secure and confidential video sessions
  • Critical tools for improved outcomes and personalized care
  • Easy to use software with fast learning curve for specialists
  • Secured encrypted system that is HIPAA and GDPR compliant
  • High engagement features and gamification that improve user experience

The team of mental health professionals that led the product design at Mindleap comprise of four PHD’s including leading neuroscientists, psychotherapists, and clinical psychologists. Mindleap’s CTO Simon Abou-Antoun has 10+ years of technical leadership, managing large projects and developing custom solutions for companies including Amazon, Scotia Bank and Fiat Chrysler. Simon commented: “We have gathered a strong team with different sets of skills ranging from software developers, UX/UI designers and IOS and Android experts. Our full stack, frontend, backend, Cloud and QA specialists are currently focused on ensuring all requirements are met so we can launch Mindleap by the end of summer.”

Mindleap’s founder and CEO Nikolai Vassev brings a unique skillset to the company as he has proven experience driving top line software licensing and SAAS revenue into some of the largest organizations in the world. During his career he has sold millions of dollars worth of cybersecurity and data analytics solutions and understands the intricacies of successfully implementing software solutions that are bringing value to customers, partners, and end users. Nikolai will be representing Mindleap and Mydecine at the “Investing in Psychedelics” event put together by the Canadian Securities Exchange, and CFN Media along with other industry executives and experts. You can register to attend for free here and can tune in on June 17 starting at 12:00pm PDT.

Nikolai Vassev, Mindleap Founder and CEO commented: “The intense anxiety and fear that many people are feeling has led to social instabilities as the virus crisis and economic collapse continues to worsen and compound already existing problems. Mindleap’s platform is set to launch in a few short months and will provide much needed support to those people suffering from depression, addiction and other mental health issues.”

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-signs-definitive-agreement-to-acquire-mindleap-healths-advanced-digital-telehealth-platform-301078673.html

June 15, 2020 - Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation

 

Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce  the establishment of a research division agreement with Applied Pharmaceutical Innovation (“API”), a translational commercial drug development institute hosted in the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences.

The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities. The Faculty of Pharmacy and Pharmaceutical Sciences is consistently ranked in the top 15 globally for the citations of research by international QS rankings in pharmacy and pharmacology and includes a wide range of experts from discovery, pharmaceutical analysis, drug action, disposition, formulation and clinical development. [1] Mydecine is also able to access broader expertise through the agreement such as API’s collaborating institute the Alberta Machine Intelligence Institute (Amii) – ranked among the top 5 institutes in the world for AI/ML[2] – as well as experts in mycology, pharmacometrics, neuropharmacology and much more at universities throughout the API network.

Through the agreement, Mydecine has the ability to immediately commence fungal discovery investigations with varietal mushrooms and their extracts, including scheduled substances. With access to GMP capacity and Health Canada licenses that include the ability to move to import and export, conduct R&D, and clinical trials Mydecine is able to begin work that will take other companies years to establish the capability for. Research and development is commencing with a significant program to extract, analyze, and determine the effects of various compounds from fungi and their pharmacokinetic disposition and development of dosage forms for specific indications, providing Mydecine with an extensive assets and capacity to become a leader in the space. The end goal is developing products with clinical applications over a period of three years.  In exchange for these services, MYCO entered into a two-year commitment and will be paying API a total $1,099,345 in year one and $1,136,249 in year two ending February 1, 2022. Year three and beyond will be a right of first refusal to either party.

“We see this agreement as a core component of our work as a company,” says Mydedine CEO Josh Bartch “the API team at the Faculty of Pharmacy and Pharmaceutical Sciences gives us the ability to rocket our product development ahead by years, providing the know-how, facilities, and licenses to quickly establish Mydecine as a leader in naturally sourced therapies for a wide variety of indications. The research division also provides a phenomenal synergy with our other recent acquisitions, giving us a dedicated team to explore myco-inspired treatments particularly for areas of high need such as mental health.”

“Our partnership with the University of Alberta will unlock brand new avenues for the study of medical uses of mushrooms,” Robert Roscow, CSO of Mydecine. “This partnership is a fundamental aspect of Mydecine’s expanding unique research network.  We are investigating the potential of mushrooms and their compounds to improve human health and wellness. This research partnership opens up, not only investigation of single molecules from mushrooms but also more complex formulations. The breadth of research resources at the University of Alberta, from world class AI to cultivation and pharmacology, as well as their possession of Health Canada License allows an unprecedented level of study.”

“Back to the fungal future,” Dr. Neal Davies, Dean, Faculty of Pharmacy and Pharmaceutical Sciences “Pharmaceutical activity of fungal metabolites have been known for at least 15 centuries and contemporary research has discovered some novel molecule leads for unique mycological medications for nature inspired treatments in the new millennium. This bodes very well for the program developing promising treatments.”

“We’re thrilled to be working with Mydecine,” says API CEOAndrew MacIsaac, “we see their focus as one of growing importance and high potential that will serve them well. By developing a world class R&D program that discovers potential new lead compounds, synergistic effects, and increased therapeutic indications for mushroom-derived products, Mydecine will stand out in this bourgeoning sector.

[1] http://csrankings.org/#/fromyear/1990/toyear/2020/index?ai&mlmining&world

https://www.topuniversities.com/university-rankings/university-subject-rankings/2020/pharmacy-pharmacology  (Sort by ranking indicator citations per paper)

[2] https://investalberta.ca/industry-profiles/artificial-intelligence/

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-inc-signs-partnership-agreement-with-applied-pharmaceutical-innovation-301076608.html

June 12, 2020 - Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation

 

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce the establishment of a research division agreement with Applied Pharmaceutical Innovation (“API”), a translational commercial drug development institute hosted in the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences.

The agreement with API provides exceptional capacity for Mydecine and the ability to significantly speed their product development with leading experts in the pharmaceutical sciences and established drug development facilities. The Faculty of Pharmacy and Pharmaceutical Sciences is consistently ranked in the top 15 globally for the citations of research by international QS rankings in pharmacy and pharmacology and includes a wide range of experts from discovery, pharmaceutical analysis, drug action, disposition, formulation and clinical development.[1] Mydecine is also able to access broader expertise through the agreement such as API’s collaborating institute the Alberta Machine Intelligence Institute (Amii) – ranked among the top 5 institutes in the world for AI/ML[2] – as well as experts in mycology, pharmacometrics, neuropharmacology and much more at universities throughout the API network.

Through the agreement, Mydecine has the ability to immediately commence fungal discovery investigations with varietal mushrooms and their extracts, including scheduled substances. With access to GMP capacity and Health Canada licenses that include the ability to move to import and export, conduct R&D, and clinical trials Mydecine is able to begin work that will take other companies years to establish the capability for. Research and development is commencing with a significant program to extract, analyze, and determine the effects of various compounds from fungi and their pharmacokinetic disposition and development of dosage forms for specific indications, providing Mydecine with an extensive assets and capacity to become a leader in the space. The end goal is developing products with clinical applications over a period of three years.  In exchange for these services, MYCO entered into a two-year commitment and will be paying API a total $1,099,345 in year one and $1,136,249 in year two ending February 1, 2022. Year three and beyond will be a right of first refusal to either party.

“We see this agreement as a core component of our work as a company,” says Mydedine CEO Josh Bartch, “the API team at the Faculty of Pharmacy and Pharmaceutical Sciences gives us the ability to rocket our product development ahead by years, providing the know-how, facilities, and licenses to quickly establish Mydecine as a leader in naturally sourced therapies for a wide variety of indications. The research division also provides a phenomenal synergy with our other recent acquisitions, giving us a dedicated team to explore myco-inspired treatments particularly for areas of high need such as mental health.”

“Our partnership with the University of Alberta will unlock brand new avenues for the study of medical uses of mushrooms,” Robert Roscow, CSO of Mydecine. “This partnership is a fundamental aspect of Mydecine’s expanding unique research network. We are investigating the potential of mushrooms and their compounds to improve human health and wellness. This research partnership opens up, not only investigation of single molecules from mushrooms but also more complex formulations. The breadth of research resources at the University of Alberta, from world class AI to cultivation and pharmacology, as well as their possession of Health Canada License allows an unprecedented level of study.”

“Back to the fungal future,” Dr. Neal Davies, Dean, Faculty of Pharmacy and Pharmaceutical Sciences “Pharmaceutical activity of fungal metabolites have been known for at least 15 centuries and contemporary research has discovered some novel molecule leads for unique mycological medications for nature inspired treatments in the new millennium. This bodes very well for the program developing promising treatments.”

“We’re thrilled to be working with Mydecine,” says API CEO, Andrew MacIsaac, “we see their focus as one of growing importance and high potential that will serve them well. By developing a world class R&D program that discovers potential new lead compounds, synergistic effects, and increased therapeutic indications for mushroom-derived products, Mydecine will stand out in this bourgeoning sector.

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-inc-signs-partnership-agreement-with-applied-pharmaceutical-innovation-301075238.html

June 10, 2020 - Mydecine Innovations Group to Acquire NeuroPharm Inc.

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) (“Mydecine” or the “Company”), is pleased to announce it has signed a non-binding Letter of Intent (“LOI”) dated June 9, 2020 to acquire NeuroPharm Inc., (“NeuroPharm”) a Canadian-based healthcare company working to deploy the power of nature’s medicine for the wellness of veterans, EMS and front line personnel in  North America and globally (the “Acquisition”).

“The exceptional roles and responsibilities Canada’s military and veterans, EMS and front-line personnel undertake on a daily basis, contribute to these professional’s underlying mental health challenges” said Josh Bartch, CEO, Mydecine Innovations Group. “I look forward to working with NeuroPharm’s talented clinicians, scientists, academics  and industry leaders focused on responding to these individual’s mental health and wellness needs in the years to come.”

“Our mission is to build a capability that will truly have a focus on veterans, EMS and other front-line personnel.  This new capability will bring to the table unique skillsets to meet this enormous challenge of building veterans, EMS and front-line staff confidence and restoring their overall wellness. With our experienced team, we understand their unique circumstances related to service that may have contributed to operational stress injuries namely post-traumatic stress disorder (PTSD), depression or anxiety” added Colonel (Ret’d) Pucci, Chairman and CEO NeuroPharm Inc.

Mydecine and NeuroPharm will combine to focus on an integrated health and wellness research strategy and the development of products underpinned by therapies to assist veterans with mental health issues. NeuroPharm is focused on developing unique pharmaceutical and natural health products for veteran wellness , with a specific focus on the use of psilocybin. Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. NeuroPharm has developed unique and proprietary technology to treat various mental health conditions that are frequently experienced by veterans such as PTSD, depression, addiction, anxiety, and panic disorders as well as migraine and cluster headaches. Preliminary studies from institutions including the Imperial College of London, University of Zurich, Johns Hopkins, NYU, and UCLA suggest that psilocybin-assisted therapy could be a revolutionary treatment for depression and addiction.

 For Full Press Release – https://www.prnewswire.com/news-releases/mydecine-innovations-group-to-acquire-neuropharm-inc-301073278.html

June 2, 2020 - Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado

NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE: 0NF) (“NewLeaf Brands” or the “Company“), soon to put into effect its name change to Mydecine Group, is pleased to announce the completion of its wholly-owned and operated world class R&D Lab and Facilities focused on the mycology of the  fungtional© mushroom space.

Earlier last year, Denver became the first U.S. city to decriminalize mushrooms containing the psychedelic substance psilocybin. The proposal, Initiative 301, suggested making both personal use and possession of psilocybin mushrooms among people 21 and older, the lowest possible law enforcement priority in Denver. In addition, the Initiative prohibits the city from spending resources to pursue criminal penalties related to the use or possession of psilocybin mushrooms among people 21 and older. Now, Mydecine’s research and product development lab and facilities will be the first of its type in North America and demonstrates the Company’s aggressive plans and approach in leading this exciting space into the future. 

“With the addition of Rob Roscow as CSO, I’m incredibly excited to move into our 7,500 sq. ft. lab in Colorado,” Josh Bartch, CEO of NewLeaf Brands, said. “Opening this lab gives us the opportunity to develop unique IP revolving around a number of exotic breeds of fungi. For ages, varieties of mushrooms have been used in Eastern medicines to help treat many types of ailments and have been known to hold immense health benefits.  We know the various compounds work but there’s a lot to be discovered as to why there is, which holds a vast potential blue sky to improve the efficiency and efficacy of these various compounds.” 

The Lab will be run by Mydecine’s CSO Rob Roscow and Dr. Mali Reddy, a seven-time Nobel peace prize nominee, along with a number of associate scientists. The Company will also continue to expand on the build out by adding additional staff and equipment to the new headquarters lab in Denver to strengthen Mydecine’s research and development capacities. The 7,500 sq. ft. facility will serve as a central hub for all of Mydecine’s research and will spearhead the Company’s investigation into fungtional mushrooms for human wellness. The facility will be housed in a purposely renovated lab space; Dr. Mali Reddy, a scientific advisor to Mydecine, previously utilized this space to run FDA compliant testing on food products. This prior use has greatly accelerated the timeline of renovation and allowed for repurposing of expensive industrial and scientific equipment, saving Mydecine both time and funds in the process of establishing this cutting-edge facility.

The facility will house state-of-the-art chemical analysis, genomic sequencing, purification, and tissue culture capabilities. Mydecine will use this capacity to leverage knowledge found in traditional medicine, and academic literature, for new innovations. Fungtional mushrooms have long been held in high regard for their healing properties by cultures around the world. This potential for healing is not well developed in modern society. As such, Mydecine will use its research to drive the development of products that give the consumer full access to this healing potential.

“We strongly believe in the power that fungtional© mushroom compounds and formulations will be able to provide. Similar to cannabis with its hundreds of various chemical profiles, varieties of fungi also provide a pharmacopoeia of hundreds if not thousands of unique chemical properties that are beneficial for human consumption. Our genetics and pharmacology teams are currently trying to define exactly what these chemicals can be used for independently and also synergistically to take both a mono and poly pharmacological approach toward developing retail products where the outside label matches the ingredients within. We will start with the infusion of simple common products with the extracts from fungi varieties such as lion’s mane mushroom and mycelium, reishi, cordyceps, turkey tail, to name a few that the general market can relate to rather easily at first and build out the portfolio bigger each year in parallel with our educational and marketing platforms,” said Damon Michaels, COO of NewLeaf Brands.

Mydecine is assembling an expansive and highly capable ecosystem of resources designed to unlock the healing and wellness power of fungi. The Company strongly believes in the untapped potential of fungi for the betterment of the human condition and that this potential will only be fully available to everyone with a much better understanding of mushrooms and their compounds; this understanding will require pointed research to uncover and Mydecine is currently conducting this research with in-house resources and partnerships.

 For Full Press Release – https://www.prnewswire.com/news-releases/newleaf-brands-announces-its-move-into-state-of-the-art-7-500-sq-ft-specialty-mycology-rd-and-product-development-lab-in-denver-colorado-301068963.html

June 1, 2020 - NewLeaf Brands Announces Name and Stock Ticker Symbol Change to Mydecine Innovations Group Inc. (CSE: MYCO)

NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE: 0NF) (“NewLeaf Brands” or the “Company“) is pleased to announce that it has changed its name from NewLeaf Brands Inc. to Mydecine Innovations Group Inc. and its ticker symbol from ‘NLB’ to ‘MYCO’. Subject to approval of the Canadian Securities Exchange (the “CSE”), the Company expects the name and symbol change to take effect on June 2, 2020 when its common shares will begin trading on the CSE under the new name ‘Mydecine Innovations Group Inc.’ and new ticker symbol ‘MYCO’. 

Pursuant to the Company’s recent acquisition of Mydecine Group, the Company’s fundamental business continues to be the development of innovative products in the Naturally Sourced Therapies (NST) space, comprised of the hemp, cannabis, and psilocybin markets. Accordingly, the company believes that the name and ticker symbol change reflects an initiative to align the Company’s brand with this new strategic focus. The name change was approved by the board of directors on May 26, 2020. 

No action is required by existing shareholders with respect to the name and ticker symbol change.  Certificates representing common shares of NewLeaf Brand Inc. will not need to be exchanged as a result of the name change.

 For Full Press Release – https://www.prnewswire.com/news-releases/newleaf-brands-announces-name-and-stock-ticker-symbol-change-to-mydecine-innovations-group-inc-cse-myco-301068306.html

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For mydecine innovations group inc., financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.